<DOC>
	<DOCNO>NCT00190307</DOCNO>
	<brief_summary>The STRATAGEM trial investigator-driven French nationwide multicenter , randomize , double-blind , placebo-controlled trial compare perioperative low-dose aspirin therapy versus placebo perioperative period patient document symptomatic stable atherothrombotic disease take antiplatelet therapy undergo non-coronary surgery .</brief_summary>
	<brief_title>STRATAGEM : Strategy Managing Antiplatelet Therapy Perioperative Period Non Coronary Surgery</brief_title>
	<detailed_description>There little evidence guide antiplatelet therapy patient high risk atherothrombotic event undergo non cardiac surgery . Specifically , uncertain whether patient currently antiplatelet therapy continue continue treatment perioperative period . Aim : To determine evidence-based strategy manage antiplatelet therapy perioperative period . Methods : The STRATAGEM trial investigator-driven French nationwide multicenter , randomize , double-blind , placebo-controlled trial compare perioperative low-dose aspirin therapy versus placebo perioperative period patient document symptomatic stable atherothrombotic disease take antiplatelet therapy undergo non-coronary surgery . The trial involve 1500 patient high risk atherothrombosis , currently receive long-term antiplatelet therapy schedule non-coronary surgery 50 center . Ten day prior surgery , patient discontinue antiplatelet therapy randomly assign either 75 mg aspirin match placebo 10 day surgical procedure . Usual therapy resume surgery accord local practice . The main outcome measure composite endpoint day 30 reflect serious perioperative complication , i.e . total mortality , severe ischemic event ( ischemic stroke , non-fatal myocardial infarction [ MI ] , acute limb ischemia , clinical deep venous thrombosis ) and/or major hemorrhage ( life-threatening bleeding conducive revision , redo surgery , cerebral hemorrhage , intra- retroperitoneal bleeding , bleed result transfusion 2 unit pack red blood cell ) . The hypothesis test low-dose aspirin associate net clinical benefit compare placebo prevention severe perioperative thrombotic hemorrhagic complication .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Written inform consent Patients eighteen year age Patients treat oral antiplatelet agent secondary prevention ( i.e . establish symptomatic cardiovascular disease ) : regardless reason ( coronary artery disease , stroke TIA [ transient ischemic attack ] , peripheral arterial disease ) regardless antiplatelet agent ( aspirin , clopidogrel , ticlopidine , dipyridamole ) . Patients scheduled intermediate highrisk surgery , include limited : long procedure associate hemodynamic variation major blood loss valvular surgery thoracic surgery orthopedic surgery general ( intraperitoneal ) surgery urological surgery vascular surgery ear , nose , throat ( ENT ) cancerologyrelated surgery . Coronary bypass graft surgery History thrombocytopenia allergy heparin Arterial stent placement within previous 30 day Active bleed Formal contraindication use anticoagulant aspirin Recent acute coronary syndrome Ophthalmological surgery ( posterior chamber ) Neurosurgery Emergency surgery Thrombotic bleeding risk deem unacceptable surgical anesthetic team Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Long term antiplatelet therapy</keyword>
	<keyword>Scheduled surgery</keyword>
</DOC>